CyMedica Orthopedics today said it completed early enrollment of 159 patients in an FDA-regulated clinical trial of its E-Vive pain relief technology.
The technology is designed for patients with knee osteoarthritis and is being studied in a randomized, prospective, double-blind, multisite, pivotal trial in adults. The trial will evaluate the company’s patented CyMotion neuromuscular strengthening technology for reducing pain and increasing function and subjects that have knee osteoarthritis compared to similar sham-controlled systems.
CyMedica’s technology is home-based therapy with remote monitoring capabilities. Study participants had the opportunity to continue treatment and participation in the trial while being unable to attend in-office appointments due to the COVID-19 pandemic.
“At CyMedica, we recognize the significant unmet needs for patients living with painful knee osteoarthritis,” president and CEO Robert Morocco said…